Sign up
Pharma Capital

Living Cell Technologies' shares slump 85% at the open

Results from the clinical trial were disappointing.
Shares will fall at the open

Living Cell Technologies Ltd's (ASX:LCT) shares have plunged 85.4% to $0.03 on heavy volume in the first 15 minutes of trade, following the top-line results of the company's Parkinson’s trial.

The Phase IIb clinical study of NTCELL® for Parkinson’s disease have been unblinded.

Three of the four primary endpoints were met.

The company noted that at 26 weeks post implant, there is not a statistically significant difference between the groups who received NTCELL and the patients who had sham surgery, as measured by the change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state).

Dr Ken Taylor, chief executive officer, said that the company is disappointed in the results.

Register here to be notified of future LCT Company articles
View full LCT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.